Skip to content

13F-HR filed by Caligan Partners LP

Caligan Partners LP filed this 13F-HR for the quarter ended 2023-06-30, filed 2023-08-14, with 13 holding rows worth $177,813,962.

Accession
0001727492-23-000009
Filed
2023-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2023

A holdings report, 13 entries on the cover page, a total value of $177,813,962 stated on the cover page (in dollars after the unit check, H1), rows summing to $177,813,962 with VALUE read as dollars as filed, 13F file number 028-23096. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
LIQUIDIA CORPORATION COM NEW53635D202Stock9,243,627$72,562,472dollars as filed
ANIKA THERAPEUTICS INC035255108COM720,291$18,713,160dollars as filed
EXELIXIS INC COM30161Q104Stock910,730$17,404,050dollars as filed
STANDARD BIOTOOLS INC34385P108COM8,467,920$16,343,086dollars as filed
INTERCEPT PHARMACEUTICALS IN45845P108COM1,293,510$14,306,221dollars as filed
INTERCEPT PHARMACEUTICALS IN45845P958COM1,200,000$13,272,000dollars as filedput
EVOLUS INC30052C107COM1,760,136$12,796,189dollars as filed
VERONA PHARMA PLC925050106SPONSORED ADS183,064$3,869,973dollars as filed
ADMA BIOLOGICS INC000899104COM847,513$3,127,323dollars as filed
EYEPOINT INC COM NEW30233G209Stock310,298$2,699,593dollars as filed
ALIMERA SCIENCES INC016259202COM478,777$1,398,029dollars as filed
SOCIETAL CDMO INC75629F109COM1,077,268$1,184,995dollars as filed
AGIOS PHARMACEUTICALS INC00847X104COM4,833$136,871dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001727492-23-000009this filing2023-08-14acceptance time not in the bulk data set